Combinatorial therapeutic approaches targeting both EGFR and MET have been tested clinically—predominantly in the context of EGFR-driven cancers with MET-mediated acquired resistance—and have shown promising results, supporting the benefit of this approach for NSCLC treatment. This evidence concerns the gene MET and cancer.